This is a preview of subscription content, log in via an institution to check access.
Notes
The study was affiliated with Novartis.
Reference
Ezzat H, et al. Economic Burden of Sickle Cell Disease in the Middle East. 26th Congress of the European Haematology Association : abstr. EP1220, 9 Jun 2021. Available from: URL: https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324941/h.ezzat.economic.burden.of.sickle.cell.disease.in.the.middle.east.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2035%2Aot_id%3D25576%2Amarker%3D1286%2Afeatured%3D17286
Rights and permissions
About this article
Cite this article
Sickle cell disease associated with high costs in the Middle East. PharmacoEcon Outcomes News 884, 28 (2021). https://doi.org/10.1007/s40274-021-7935-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7935-1